Paul D Sforza

Learn More
Scleral buckling is an excellent procedure for retinal reattachment but can induce disabling refractive errors. Laser in situ keratomileusis (LASIK) has been proven effective for the reduction of refractive errors induced by ophthalmic surgery. We describe the case of a 53-year-old man who developed symptomatic anisometropia after placement of a scleral(More)
PURPOSE To define a practice pathway for the evaluation of sixth-nerve palsies (SNPs) and to determine its cost-effectiveness and validity in a retrospective chart review. METHODS A Medline search of the English-language literature from 1966 to 1995 was performed to define the available clinical evidence and develop the practice pathway. The authors(More)
PURPOSE To evaluate the effect on intraocular pressure (IOP) of substituting topical Cyclosporine A 0.5% for topical corticosteroids in patients with postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH). We also sought to determine the penetration of topical 0.5% Cyclosporine A into the cornea and anterior chamber. METHODS(More)
PURPOSE To determine the safety and effectiveness of laser in situ keratomileusis (LASIK) for visual rehabilitation of residual myopia and astigmatism after penetrating keratoplasty. DESIGN Prospective, noncomparative case series. PARTICIPANTS LASIK was performed on 23 eyes of 22 patients unable to wear glasses or contact lenses after penetrating(More)
Pituitary adenoma is an uncommon intracranial tumor of children. The authors retrospectively reviewed the records of 10 patients younger than 17 years of age with pituitary adenoma. Five patients had visual loss at presentation. Four of these five patients with visual loss and extrasellar tumor extension were adolescents (12-15 years of age). Seven of 10(More)
PURPOSE The authors performed a prospective evaluation of the efficacy of treating ocular cicatricial pemphigoid (OCP) with subconjunctival mitomycin C. DESIGN Unmasked, prospective, internally controlled case series. METHODS Patients were eligible for treatment with subconjunctival mitomycin C under three criteria: (1) significant complications of(More)
  • 1